The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.
 
Omid Hamid
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Immunocore (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Rinat (Inst); Roche (Inst)
 
Caroline Robert
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - Genoptix; GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Consulting or Advisory Role - Amgen; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Wen-Jen Hwu
Consulting or Advisory Role - Merck
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck/Schering Plough
 
Richard Kefford
Honoraria - Bristol-Myers Squibb; Merck; Novartis
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); TEVA (Inst)
Speakers' Bureau - GlaxoSmithKline; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Adaptive Biotechnologies; Imvaq Therapeutics; Potenza Therapeutics; Serametrix; Tizona Therapeutics, Inc.; Trieza Therapeutics
Honoraria - Regeneron
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Ascentage Pharma; Beigene; Bristol-Myers Squibb; Chugai Pharma; FSC Pediatrics; Genentech; Lilly; MedImmune; Merck; Ono Pharmaceutical; Polaris; Polynoma; Potenza Therapeutics; Sellas Life Sciences; Tizona Therapeutics, Inc.
Research Funding - Bristol-Myers Squibb (Inst); F-Star Therapeutics; Genentech/Roche (Inst); Incyte (Inst); Leap Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Janssen; Ono Pharmaceutical; Roche
 
Peter Hersey
No Relationships to Disclose
 
Richard Wayne Joseph
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Exelixis; Genoptix; Merck (Inst); Nektar; Novartis
Research Funding - Amgen (Inst); Bristol-Myers Squibb; Merck; Roche/Genentech (Inst); X4 Pharma (Inst)
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Biond; Celldex; CytomX Therapeutics
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche; Sellas Life Sciences; WindMIL
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche; Sellas Life Sciences; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Novartis; Pieris Pharmaceuticals; Roche
 
Roxana Stefania Dronca
Research Funding - Merck Sharp & Dohme (Inst)
Other Relationship - Elsevier
 
Tara C. Mitchell
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Roche (Inst)
 
Amita Patnaik
Consulting or Advisory Role - Bayer
Research Funding - Abbvie; Aeglea Biotherapeutics; Alexion Pharmaceuticals; Amgen; Asana Biosciences; Ascentage Pharma Group; Astex Pharmaceuticals; AVEO (Inst); Bayer; Bayer (Inst); Calithera Biosciences; Celgene (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Endocyte (Inst); Five Prime Therapeutics (Inst); Formation Biologics (Inst); Forty Seven; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jiangsu Hengrui Medicine; Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Merck Sharp & Dohme; Novartis; OncoMed; Pfizer (Inst); Plexxikon; Plexxikon (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst); Tesaro (Inst); Tesaro (Inst); Teva (Inst); Upsher-Smith; Zymeworks (Inst)
 
Hassane M. Zarour
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Tesaro (Inst)
 
Anthony M. Joshua
No Relationships to Disclose
 
Erin Jensen
Employment - Merck
 
Nageatte Ibrahim
Employment - Merck
Stock and Other Ownership Interests - GlaxoSmithKline; Merck
 
Sama Ahsan
Employment - Merck
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Johns Hopkins Hospital
Travel, Accommodations, Expenses - Merck; Merck (I)
 
Antoni Ribas
Stock and Other Ownership Interests - Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; PACT Pharma; Tango Therapeutics
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis